Northern Trust Corp Acquires 94,858 Shares of Genmab A/S (NASDAQ:GMAB)

Northern Trust Corp increased its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 599,381 shares of the company's stock after purchasing an additional 94,858 shares during the quarter. Northern Trust Corp owned about 0.09% of Genmab A/S worth $12,509,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GMAB. Crossmark Global Holdings Inc. boosted its stake in Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company's stock valued at $868,000 after acquiring an additional 3,377 shares during the last quarter. SG Americas Securities LLC boosted its stake in Genmab A/S by 82.7% in the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company's stock valued at $551,000 after acquiring an additional 11,949 shares during the last quarter. Blue Trust Inc. boosted its stake in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after acquiring an additional 1,442 shares during the last quarter. R Squared Ltd bought a new position in Genmab A/S in the fourth quarter valued at approximately $93,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after acquiring an additional 827 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Stock Up 2.5%

Shares of NASDAQ:GMAB traded up $0.51 during midday trading on Thursday, reaching $21.03. 1,967,679 shares of the company were exchanged, compared to its average volume of 1,126,099. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $29.96. The stock has a fifty day simple moving average of $19.76 and a two-hundred day simple moving average of $20.71. The firm has a market cap of $13.48 billion, a PE ratio of 12.09, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.